Target intelligence / Profile preview

Immunoglobulin kappa variable 1-27 (IGKV1-27)

Target
IGKV1-27
Molecular classification
Other (Immunoglobulin variable region; not a classical receptor, enzyme, transporter, or transcription factor)
01

Overview

Immunoglobulin kappa variable 1-27 (IGKV1-27) encodes the variable (V) region of the kappa light chain in human immunoglobulins (antibodies). This variable domain forms part of the antigen binding site, pairing with a variable heavy chain to create antibody specificity. The gene participates in the assembly of functional immunoglobulins through V-J (variable-joining) recombination in developing B cells, contributing to the diversity of the humoral immune response. IGKV1-27 is not a classical drug target or receptor but a gene segment involved in immune recognition processes. It plays a potential (though not unique) role in disease through its contribution to antibody specificity and, in rare cases, via RNA editing impacts observed in some cancers. No approved therapeutic drugs are known to interact directly with this variable region, though antibodies utilizing IGKV1-27 as part of their repertoire may have therapeutic or diagnostic uses.

Other names
IGKV1-27IGKV127A20
02

Mechanism of action

Not applicable (antibodies as a class may be engineered to include this variable region for antigen binding, but IGKV1-27 itself is not directly drug-targeted)

03

Biological functions

Immune responseAntigen recognition
04

Disease associations

Cancer (possible modulation via RNA editing in cancer)Other (primary immune function context)

Beyond the preview

Go deeper on Immunoglobulin kappa variable 1-27 (IGKV1-27).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin kappa variable 1-27 (IGKV1-27).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call